Medullary Thyroid Carcinoma
📧 Sign up to get email alerts when something new happens for Medullary Thyroid Carcinoma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-05-14FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)
The FDA approved a supplemental application for CAPRELSA (vandetanib) submitted by Genzyme Corporation. This action updates the existing NDA…
-
CLINICAL_TRIALS research · 2025-04-30Clinical Trial Update: Thermal Ablation of Cervical Metastases From Thyroid Carcinoma [NA]
Clinical trial update shows a study of thermal ablation for cervical metastases from thyroid carcinoma is currently active but not recruitin…
-
CLINICAL_TRIALS research · 2025-02-28Clinical Trial Update: PET-TC in Thyroid Evaluation
Clinical trial update indicating that PET-CT is being explored for thyroid evaluation in patients with medullary thyroid carcinoma and parat…
-
CLINICAL_TRIALS trial_result · 2025-02-24Clinical Trial Update: 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer. [Phase 1]
Phase 1 clinical trial evaluating the radiopharmaceutical 177Lu-PP-F11N for receptor-targeted therapy and imaging in metastatic medullary th…
-
CLINICAL_TRIALS approval · 2025-01-17Clinical Trial Update: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Eli Lilly's RET inhibitor selpercatinib (Retevmo) has been approved for marketing to treat cancers driven by RET activation, including non-s…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-01-03Clinical Trial Update: Predictive Factors for Medullary Thyroid Cancer Aggressiveness
This clinical trial examines predictive factors associated with the aggressiveness of medullary thyroid carcinoma and has completed.
-
CLINICAL_TRIALS trial_result · 2024-12-18Clinical Trial Update: Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer
An observational trial update evaluating vandetanib in RET +/- patients with metastatic medullary thyroid carcinoma has completed.
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Spanish Study for Molecular Characterization of Thyroid Carcinoma
A Spanish study conducted by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello is pursuing molecular characterization of thyroid ca…
-
CLINICAL_TRIALS research · 2024-07-26Clinical Trial Update: Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Clinical study from Universidad Nacional Autónoma de México exploring genetic factors underlying neuroendocrine neoplasms. The trial is curr…
-
CLINICAL_TRIALS research · 2024-07-25Clinical Trial Update: Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma [Phase 1]
A Phase 1 head-to-head clinical trial comparing two Ga-68 PET tracers (68Ga-MGS5 vs 68Ga-DOTATATE) in patients with medullary thyroid carcin…
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer [Phase 3]
Phase 3 study of selpercatinib (Retevmo) in RET-mutant medullary thyroid carcinoma has results posted (June 13, 2024); the trial is currentl…
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations [Phase 1, Phase 2]
A study of TPX-0046, a RET/SRC inhibitor, in adults with advanced solid tumors including non-small cell lung cancer and medullary thyroid ca…
-
FDA approval · 2024-06-12FDA Approved: RETEVMO — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for RETEVMO (selpercatinib) from Eli Lilly and Company.
-
FDA approval · 2024-04-10FDA Approved: RETEVMO — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for RETEVMO (selpercatinib) from Eli Lilly, expanding its labeled indications for RET fusion–positiv…
-
CLINICAL_TRIALS withdrawal · 2024-01-05Clinical Trial Update: A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). [Phase 3]
A Phase 3 trial comparing pralsetinib to standard of care in RET-mutated medullary thyroid cancer has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2023-11-15Clinical Trial Update: A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer [Phase 2]
Phase 2 study assessing regorafenib as second or third line therapy for metastatic medullary thyroid carcinoma; results have been posted.
-
CLINICAL_TRIALS trial_result · 2023-07-25Clinical Trial Update: Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma [Phase 4]
Phase 4 trial investigating anlotinib in patients with advanced medullary thyroid carcinoma is currently recruiting.
-
FDA approval · 2023-04-13FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for CAPRELSA (vandetanib) submitted by Genzyme Corporation. The supplemental submission has been app…
-
CLINICAL_TRIALS trial_result · 2022-07-26Clinical Trial Update: ImmunoTEP for Patients With Medullary Thyroid Carcinoma. [Phase 1, Phase 2]
Phase 1/2 clinical trial update for ImmunoTEP in patients with Medullary Thyroid Carcinoma (completed).
-
CLINICAL_TRIALS trial_result · 2022-06-02Clinical Trial Update: A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation [Phase 2]
Phase 2 study of selpercatinib (Retevmo) in adults with advanced RET-altered solid tumors, including RET fusion–positive cancers and medulla…
-
FDA approval · 2022-03-28FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)
The FDA approved a supplemental application for CAPRELSA (vandetanib) submitted by Genzyme Corporation.
-
CLINICAL_TRIALS trial_result · 2022-02-23Clinical Trial Update: A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) [Phase 2]
Phase 2 clinical trial update for HA121-28 tablets in medullary thyroid carcinoma, status not disclosed.
-
CLINICAL_TRIALS trial_result · 2020-12-22Clinical Trial Update: Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer [Phase 1, Phase 2]
Clinical trial update on vandetanib for children and adolescents with medullary thyroid carcinoma, including conditions related to multiple …
-
FDA approval · 2020-10-22FDA Approved: COMETRIQ — Supplemental Application (Exelixis, Inc.)
FDA approved a supplemental application for COMETRIQ (cabozantinib) submitted by Exelixis, Inc. The action updates the labeling for the prod…
-
CLINICAL_TRIALS trial_result · 2020-07-31Clinical Trial Update: Nintedanib(BIBF1120) in Thyroid Cancer [Phase 2]
Phase 2 trial of nintedanib (BIBF1120) in thyroid cancer (medullary and differentiated thyroid cancer) has completed.